Nutriband Inc. (NTRB)
| Market Cap | 133.42M |
| Revenue (ttm) | 943,702 |
| Net Income (ttm) | -2.93M |
| Shares Out | 6.36M |
| EPS (ttm) | -0.51 |
| PE Ratio | n/a |
| Forward PE | 526.32 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 16 |
| Last Price | $20.99 |
| Previous Close | $21.00 |
| Change ($) | -0.01 |
| Change (%) | -0.05% |
| Day's Open | 21.00 |
| Day's Range | 20.99 - 21.00 |
| Day's Volume | 315 |
| 52-Week Range | 3.00 - 32.00 |
News
There are no news available yet.
About NTRB
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain. Its product line consists of an energy patch line; a weight management patch line; a multivitamin patch line; a children's multivitamin patch line; an amino acid patch line; an anti-wrinkle patch line; an insect repellant patch line; a detox patch line; a PMS... [Read more...]
| Industry Biotechnology | |
| Stock Exchange OTCMKTS | Ticker Symbol NTRB |
Financial Performance
In 2020, Nutriband's revenue was $943,702, an increase of 154.61% compared to the previous year's $370,647. Losses were -$2.93 million, 7.76% more than in 2019.
Analyst Forecasts
The average 12-month stock price forecast for Nutriband is 24.00, which is an increase of 14.34% from the latest price.